(VIANEWS) – NVIDIA (NVDA), Focus Financial Partners (FOCS), Air Lease Corporation (AL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
172% sales growth and 40.22% return on equity
NVIDIA Corporation provides graphics, and compute and networking solutions in the United States, Taiwan, China, and internationally. The company's Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building 3D designs and virtual worlds. Its Compute & Networking segment provides Data Center platforms and systems for AI, HPC, and accelerated computing; Mellanox networking and interconnect solutions; automotive AI Cockpit, autonomous driving development agreements, and autonomous vehicle solutions; cryptocurrency mining processors; Jetson for robotics and other embedded platforms; and NVIDIA AI Enterprise and other software. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, independent software vendors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants. It has a strategic collaboration with Kroger Co. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, NVIDIA has a trailing twelve months EPS of $4.14.
PE Ratio
NVIDIA has a trailing twelve months price to earnings ratio of 100.88. Meaning, the purchaser of the share is investing $100.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NVIDIA’s EBITDA is 34.29.
Sales Growth
NVIDIA’s sales growth for the next quarter is 172%.
Volume
Today’s last reported volume for NVIDIA is 29727300 which is 40.01% below its average volume of 49556400.
Yearly Top and Bottom Value
NVIDIA’s stock is valued at $417.64 at 20:22 EST, way under its 52-week high of $502.66 and way higher than its 52-week low of $108.13.
Previous days news about NVIDIA(NVDA)
- According to Zacks on Friday, 22 September, "Some better-ranked stocks from the broader technology sector are Asure Software (ASUR Quick QuoteASUR – Free Report) , NVIDIA (NVDA Quick QuoteNVDA – Free Report) and Dell (DELL Quick QuoteDELL – Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. "
- According to Zacks on Friday, 22 September, "Most of the fund’s holdings were in companies like NVIDIA Corp. (32.2%), Marvell Technology, Inc. (8.3%), and NXP Semiconductors N.V. (8.1%) as of May 31, 2023.FSELX’s 3-year and 5-year returns are 30.4% and 27.6%, respectively. ", "Most of the fund’s holdings were in companies like Microsoft Corp. (8.2%), NVIDIA Corp. (8%) and Apple Inc. (7.7%) as of Apr 30, 2023.KTCAX’s 3-year and 5-year returns are 6.5% and 13.8%, respectively. "
- According to Zacks on Friday, 22 September, "To that end, NVIDIA (NVDA Quick QuoteNVDA – Free Report) , iRadimed (IRMD Quick QuoteIRMD – Free Report) , Perdoceo Education (PRDO Quick QuotePRDO – Free Report) and Axcelis Technologies (ACLS Quick QuoteACLS – Free Report) have been selected as the top picks with a high net income ratio."
- According to Zacks on Friday, 22 September, "A better-ranked stock from the broader technology sector worth considering is NVIDIA Corporation (NVDA Quick QuoteNVDA – Free Report) , which sports a Zacks Rank #1. "
2. Focus Financial Partners (FOCS)
21.2% sales growth and 4.5% return on equity
Focus Financial Partners Inc. provides wealth management services to primarily ultra-high and high net worth individuals, families, and business entities. Its wealth management services include investment advice, financial and tax planning, consulting, tax return preparation, family office services, and other services. The company also offers recordkeeping and administration services; recommends financial products through commissions and distribution fees; and sells investment or insurance products. The company was founded in 2006 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Focus Financial Partners has a trailing twelve months EPS of $0.12.
PE Ratio
Focus Financial Partners has a trailing twelve months price to earnings ratio of 441.58. Meaning, the purchaser of the share is investing $441.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.5%.
3. Air Lease Corporation (AL)
17.3% sales growth and 7.78% return on equity
Air Lease Corporation, an aircraft leasing company, engages in the purchase and leasing of commercial jet transport aircraft to airlines worldwide. The company also sells aircraft from its operating lease portfolio to third parties, including other leasing companies, financial services companies, and airlines. In addition, it provides fleet management services to investors and owners of aircraft portfolios. As of December 31, 2019, the company owned a fleet of 275 aircraft, including 203 narrowbody jet aircraft and 89 widebody jet aircraft. Air Lease Corporation was founded in 2010 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, Air Lease Corporation has a trailing twelve months EPS of $4.24.
PE Ratio
Air Lease Corporation has a trailing twelve months price to earnings ratio of 9.62. Meaning, the purchaser of the share is investing $9.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.78%.
Yearly Top and Bottom Value
Air Lease Corporation’s stock is valued at $40.78 at 20:22 EST, way below its 52-week high of $46.20 and way higher than its 52-week low of $30.08.
Volume
Today’s last reported volume for Air Lease Corporation is 211193 which is 65.95% below its average volume of 620390.
4. Exelixis (EXEL)
16.2% sales growth and 6.68% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.5.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 44.22. Meaning, the purchaser of the share is investing $44.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Volume
Today’s last reported volume for Exelixis is 1396630 which is 42.53% below its average volume of 2430270.
5. Sapiens International Corporation N.V. (SPNS)
9.7% sales growth and 14.19% return on equity
Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, Europe, the Asia Pacific, and South Africa. The company offers Sapiens CoreSuite and Sapiens IDITSuite for personal, commercial, and specialty lines, as well as reinsurance and workers' compensation; and Sapiens CoreSuite, Sapiens UnderwritingPro, Sapiens ApplicationPro, Sapiens IllustrationPro, and Sapiens ConsolidationMaster for life, pension, and annuities. It also provides Sapiens DigitalSuite for insurance customers, agents, brokers, risk managers, customer groups and third-party service providers; Sapiens AgentConnect and Sapiens CustomerConnect portals; Sapiens Intelligence, an analytics platform; Sapiens IntelligencePro, a comprehensive BI solution with pre-configured reports, dashboards, and scorecards; and Sapiens Advanced Analytics, which uses AI and Machine Learning to generate actionable insights based on different models across the insurance value chain. In addition, the company offers Sapiens ReinsuranceMaster, Sapiens ReinsurancePro, and Sapiens Reinsurance GO reinsurance solutions; and Sapiens Platform, Sapiens CoreSuite, Sapiens PolicyPro, and Sapiens ClaimsPro, as well as Sapiens PolicyGo, Sapiens ClaimsGo, and Sapiens Connect for workers' compensation. Further, it provides financial and compliance solutions, which comprise Sapiens FinancialPro, Sapiens Financial GO, Sapiens StatementPro, Sapiens CheckPro, and Sapiens Reporting Tools; and Sapiens Decision, an enterprise-scale platform that enables institutions to centrally author, store, and manage various organizational business logics. Additionally, the company offers tailor-made solutions based on its Sapiens eMerge platform; and program delivery, business, and managed services. It markets and sells its products and services through direct and partner sales. The company was founded in 1982 and is headquartered in Holon, Israel.
Earnings Per Share
As for profitability, Sapiens International Corporation N.V. has a trailing twelve months EPS of $1.02.
PE Ratio
Sapiens International Corporation N.V. has a trailing twelve months price to earnings ratio of 28.78. Meaning, the purchaser of the share is investing $28.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.19%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 13.3% and 6.3%, respectively.
6. UFP Technologies (UFPT)
8.5% sales growth and 21.23% return on equity
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Earnings Per Share
As for profitability, UFP Technologies has a trailing twelve months EPS of $6.23.
PE Ratio
UFP Technologies has a trailing twelve months price to earnings ratio of 24.95. Meaning, the purchaser of the share is investing $24.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.23%.
Yearly Top and Bottom Value
UFP Technologies’s stock is valued at $155.45 at 20:22 EST, way under its 52-week high of $205.08 and way higher than its 52-week low of $80.00.
Earnings Before Interest, Taxes, Depreciation, and Amortization
UFP Technologies’s EBITDA is 3.32.
